Bridgefront Capital »

Enliven Therapeutics shares owned by Bridgefront Capital

Quarter-by-quarter ownership of Enliven Therapeutics (ELVN) shares owned by Bridgefront Capital from 13F filings

Historical chart of Bridgefront Capital investment in Enliven Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Enliven Therapeutics held by Bridgefront Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Enliven Therapeutics by Bridgefront Capital

Quarter filed Position value Share count Share price at filing
2026-03-31 $228k 5.8k 39.20

More positions owned by Bridgefront Capital

Take-Two Interactive Software (TTWO)
TPG Com Cl A (TPG)
Constellation Brands Cl A (STZ)
Broadcom (AVGO)
Encana Corporation (OVV)
Kimberly-Clark Corporation (KMB)
Clorox Company (CLX)
Lamb Weston Hldgs (LW)
Keysight Technologies (KEYS)
EQT Corporation (EQT)
Celsius Hldgs Com New (CELH)
Amgen (AMGN)
Micron Technology (MU)
Host Hotels & Resorts (HST)
Agree Realty Corporation (ADC)

View all positions for Bridgefront Capital

Top funds holding Enliven Therapeutics

OrbiMed Advisors
FMR
Polar Capital Holdings
BlackRock
Commodore Capital
Vestal Point Capital
Bellevue Group
Citadel Advisors
Fairmount Funds Management
VR Adviser
Novo A/S
State Street Corporation
Geode Capital Management
Logos Global Management
Caption Management

View all funds holding Enliven Therapeutics